Promising Outlook for Acurx Pharmaceuticals: Buy Rating Driven by Regulatory Milestones and Clinical Success of Ibezapolstat
I'm PortAI, I can summarize articles.
Matthew Keller has assigned a Buy rating to Acurx Pharmaceuticals, citing a positive opinion from the European Medicines Agency on the Pediatric Investigation Plan for ibezapolstat (IBZ). This regulatory milestone is crucial for its use in children with C. difficile infections and supports upcoming Phase 3 trials. IBZ has demonstrated a 96% Clinical Cure rate in Phase 2 trials, exceeding vancomycin's historical rate. These factors contribute to Keller's optimistic outlook for Acurx Pharmaceuticals.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments